MUMBAI (Reuters) - Dr. Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, on Tuesday posted a 25 percent rise in quarterly net profit, but fell short of analysts' estimates due to a rise in expenses.
Net profit for the January-March quarter was 4.71 billion rupees ($78.68 million), compared with 3.78 billion rupees in the same period a year ago. Analysts on average expected a profit of 6.1 billion rupees, according to Thomson Reuters data.
Dr. Reddy's, a leading player in India's $14 billion generic drugs industry, posted revenue of 25.32 billion rupees, up 17 percent from the prior year.
Shares in the Hyderabad-based company, valued at nearly $8 billion, fell 3 percent to 2,650 rupees on Tuesday after the earnings, while the Nifty was up 2 percent.
($1 = 59.8650 rupees)
(Reporting by Zeba Siddiqui in Mumbai; Editing by Matt Driskill)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app